Final Results of the Phase III VISTA Trial: VMP versus MP for Previously Untreated MM
San Miguel JF et al. Continued overall survival benefit after 5 years’ follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial. Proc ASH 2011;Abstract 476.
Dr Lonial is Vice Chair of Clinical Affairs and Director of Translational Research at the Emory University School of Medicine’s Winship Cancer Institute in Atlanta, Georgia.
|